Published on
August 5, 2022

Psychedelic Weekly Headlines | August 5th

Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.


Performance of psychedelic public companies this past week.

Company News

Braxia Scientific ($BRAX | $BRAXF) acquired KetaMD, an innovative telemedicine company focused on providing technology-facilitated ketamine-based treatments for mental health conditions. KetaMD's technology will provide Braxia the opportunity to offer in-person and digital telehealth ketamine treatments. Press Release

PharmAla Biotech ($MDMA) became an exclusive MDMA supplier to InterVivo Solutions, their client companies and affiliates. InterVivo Solutions is a pre-clinical contract research organization with expertise in neuropsychiatric and neurological diseases. Press Release

Small Pharma ($DMT | $DMTTF) has been granted a Canadian patent protecting Composition of Matter of certain deuterated analogues of DMT, including the active ingredient in their deuterated DMT candidate, SPL028.Press Release

Field Trip Health ($FTRP) received conditional listing approval from the TSX Venture Exchange for listing of common shares of Field Trip Health & Wellness. Field Trip expects Field Trip Health & Wellness Shares to begin trading on August 17, under the symbol 'FTHW'. Press Release

PharmaDrug ($PHRX | $LMLLF) announced a non-brokered offering of $650,000 of convertible secured debentures and issuances of common shares.Press Release

Mind Medicine ($MNMD | $MMED) will participate in the Canaccord Genuity 42nd Annual Growth Conference and announced that their Board of Directors has approved a 1-for-15 reverse share split of their common shares. Details


Psychedelic Finance: Interview With Julia Joyes Of TheraPsil

INN: Morgan Stanley Releases Positive Insights Report on Psychedelics

New York Post: Aaron Rodgers Says Psychedelics Led To 'Best Season Of My Career'

NBC: Oregon Psilocybin Services to finalize rules around administration, production in December 2022

National Post: Canadian Patients Fighting For Psilocybin Access Sue Federal Government

Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.